PharVision Advisers LLC Makes New $572,000 Investment in Encompass Health Co. (NYSE:EHC)

PharVision Advisers LLC purchased a new stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,192 shares of the company's stock, valued at approximately $572,000. Encompass Health makes up approximately 0.5% of PharVision Advisers LLC's portfolio, making the stock its 25th largest position.

A number of other hedge funds have also modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Encompass Health by 18.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 367,598 shares of the company's stock valued at $33,948,000 after purchasing an additional 57,130 shares in the last quarter. Woodline Partners LP grew its stake in shares of Encompass Health by 44.5% in the 4th quarter. Woodline Partners LP now owns 184,473 shares of the company's stock valued at $17,036,000 after buying an additional 56,817 shares in the last quarter. Squarepoint Ops LLC raised its position in Encompass Health by 599.0% during the fourth quarter. Squarepoint Ops LLC now owns 127,204 shares of the company's stock valued at $11,747,000 after acquiring an additional 109,007 shares in the last quarter. Twinbeech Capital LP acquired a new stake in Encompass Health in the fourth quarter valued at approximately $3,893,000. Finally, Two Sigma Advisers LP grew its position in Encompass Health by 136.3% in the fourth quarter. Two Sigma Advisers LP now owns 63,800 shares of the company's stock worth $5,892,000 after acquiring an additional 36,800 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Encompass Health

In other news, insider Elissa Joy Charbonneau sold 4,279 shares of Encompass Health stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total transaction of $498,974.19. Following the sale, the insider now directly owns 11,958 shares in the company, valued at approximately $1,394,422.38. The trade was a 26.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the transaction, the executive vice president now directly owns 79,710 shares of the company's stock, valued at $9,149,910.90. This trade represents a 11.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock worth $16,034,082 over the last three months. Company insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

EHC has been the topic of a number of recent research reports. Royal Bank of Canada raised their price target on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Barclays boosted their price target on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. William Blair reissued an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Truist Financial restated a "buy" rating and issued a $135.00 target price (up from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Finally, KeyCorp increased their price target on Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Encompass Health has a consensus rating of "Buy" and an average target price of $120.86.

Encompass Health Stock Performance

Shares of NYSE EHC opened at $121.67 on Wednesday. Encompass Health Co. has a 12 month low of $82.74 and a 12 month high of $121.96. The company has a market cap of $12.26 billion, a P/E ratio of 27.28, a P/E/G ratio of 2.31 and a beta of 0.91. The business's 50 day moving average is $106.53 and its two-hundred day moving average is $101.04. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the firm posted $1.12 earnings per share. Encompass Health's revenue was up 10.6% compared to the same quarter last year. On average, equities analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Tuesday, July 1st. Encompass Health's dividend payout ratio (DPR) is presently 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.